Literature DB >> 33129762

A proteolytic method for evaluating O-GlcNAcylation on proteins of similar molecular weight to antibody heavy chain after immunoprecipitation.

Miranda Machacek1, Patrick E Fields2, Chad Slawson3.   

Abstract

Investigating a protein of interest that runs at the same molecular weight as antibody heavy chain is a frequent deterrent to its evaluation by immunoprecipitation. Methods of minimizing the detection of the immunoprecipitating antibody are available. However, these still present a barrier to evaluating if intracellular proteins are modified by the O-GlcNAc post-translation protein modification due to interfering glycosylation on antibodies. IdeZ protease specifically cleaves antibody at the hinge region, allowing collapse of the antibody fragments to 25 kDa after denaturation. Thus, this proteolytic method uniquely allows evaluation of O-GlcNAcylation of proteins of interest formerly obscured by antibody heavy chain.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IdeZ protease; Immunoprecipitation; O-GlcNAc; Post-translational protein modification

Mesh:

Substances:

Year:  2020        PMID: 33129762      PMCID: PMC7718295          DOI: 10.1016/j.ab.2020.114001

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  20 in total

1.  Clean Western blot signals from immunoprecipitated samples.

Authors:  Ashish Lal; Susan R Haynes; Myriam Gorospe
Journal:  Mol Cell Probes       Date:  2005-12       Impact factor: 2.365

Review 2.  Modulation of transcription factor function by O-GlcNAc modification.

Authors:  Sabire Ozcan; Sreenath S Andrali; Jamie E L Cantrell
Journal:  Biochim Biophys Acta       Date:  2010-03-02

Review 3.  The impact of glycosylation on the biological function and structure of human immunoglobulins.

Authors:  James N Arnold; Mark R Wormald; Robert B Sim; Pauline M Rudd; Raymond A Dwek
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

4.  CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.

Authors:  Torbjørn Kråkenes; Ida Herdlevaer; Margrethe Raspotnig; Mette Haugen; Manja Schubert; Christian A Vedeler
Journal:  Ann Neurol       Date:  2019-06-13       Impact factor: 10.422

5.  IdeE, an IgG-endopeptidase of Streptococcus equi ssp. equi.

Authors:  Jonas Lannergård; Bengt Guss
Journal:  FEMS Microbiol Lett       Date:  2006-09       Impact factor: 2.742

6.  Elevated O-GlcNAcylation enhances pro-inflammatory Th17 function by altering the intracellular lipid microenvironment.

Authors:  Miranda Machacek; Harmony Saunders; Zhen Zhang; Ee Phie Tan; Jibiao Li; Tiangang Li; Maria T Villar; Antonio Artigues; Todd Lydic; Gentry Cork; Chad Slawson; Patrick E Fields
Journal:  J Biol Chem       Date:  2019-04-22       Impact factor: 5.157

7.  Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.

Authors:  Daniel J Cua; Jonathan Sherlock; Yi Chen; Craig A Murphy; Barbara Joyce; Brian Seymour; Linda Lucian; Wayne To; Sylvia Kwan; Tatyana Churakova; Sandra Zurawski; Maria Wiekowski; Sergio A Lira; Daniel Gorman; Robert A Kastelein; Jonathon D Sedgwick
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

8.  IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines.

Authors:  P Schwarzenberger; V La Russa; A Miller; P Ye; W Huang; A Zieske; S Nelson; G J Bagby; D Stoltz; R L Mynatt; M Spriggs; J K Kolls
Journal:  J Immunol       Date:  1998-12-01       Impact factor: 5.422

9.  Two novel IgG endopeptidases of Streptococcus equi.

Authors:  Greta Hulting; Margareta Flock; Lars Frykberg; Jonas Lannergård; Jan-Ingmar Flock; Bengt Guss
Journal:  FEMS Microbiol Lett       Date:  2009-09       Impact factor: 2.742

Review 10.  The CD4-centered universe of human T cell subsets.

Authors:  J Geginat; M Paroni; F Facciotti; P Gruarin; I Kastirr; F Caprioli; M Pagani; S Abrignani
Journal:  Semin Immunol       Date:  2013-11-01       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.